MedPath

Telehealth Exercise Platform to Reduce Frailty After Bone Marrow Transplant

Not Applicable
Completed
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Other: Exercise Intervention
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Registration Number
NCT04968119
Lead Sponsor
City of Hope Medical Center
Brief Summary

This clinical trial studies the feasibility of implementing a telehealth exercise platform to reduce frailty in patients after bone marrow transplant.

The exercise program uses a telehealth platform (e.g. smart phones, tablets or computers) to view pre-recorded exercise videos on coordination, posture, stretching, balance and resistance/aerobic training.

Physical activity may help to improve physical function, including frailty, after bone marrow transplant. Information from this trial may help researchers design future telehealth exercise routines for treating people with cancer.

Detailed Description

PRIMARY OBJECTIVE:

I. Determine the feasibility of the telehealth exercise program, as evaluated by participation and completion rates.

SECONDARY OBJECTIVE:

I. Explore the effects of the telehealth exercise program on physical functioning.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients participate in telehealth exercise sessions at home over 30 minutes with a trainer 3 days a week for 8 weeks (24 total sessions).

ARM B: Patients maintain their normal activities of daily living for 8 weeks before participating in the telehealth exercise program as described in Arm I.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
21
Inclusion Criteria
  • >= 18 years of age at the time of study enrollment
  • >= 2-years from hematopoietic cell transplantation (HCT) and in clinical remission
  • Identified as pre-frail or frail based on Bone Marrow Transplant Survivorship Study (BMTSS) questionnaire (i.e. clinically underweight, exhaustion, low energy expenditure, slow walking speed, and muscle weakness), with the presence of >= 3/5 indices classified as frail and 2/5 indices classified as prefrail
  • Able to understand and sign the informed consent document
  • Physically able and willing to complete all study procedures
  • Has access to the internet and a smartphone
  • English speaking
Exclusion Criteria
  • Overt cardiovascular disease (e.g. myocardial infarction, stroke, angina)
  • Contraindications to exercise (acute infectious disease, physical disability preventing safe performance [assistive devices], cognitive impairment or inability to cooperate)
  • Participation in regular exercise (> 60 minutes per week)
  • Female who are pregnant or planning to become pregnant

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm A (telehealth intervention)Exercise InterventionPatients participate in telehealth exercise sessions at home over 30 minutes with a trainer 3 days a week for 8 weeks (24 total sessions).
Arm A (telehealth intervention)Quality-of-Life AssessmentPatients participate in telehealth exercise sessions at home over 30 minutes with a trainer 3 days a week for 8 weeks (24 total sessions).
Arm A (telehealth intervention)Questionnaire AdministrationPatients participate in telehealth exercise sessions at home over 30 minutes with a trainer 3 days a week for 8 weeks (24 total sessions).
Arm B (delayed exercise intervention)Exercise InterventionPatients maintain their normal activities of daily living for 8 weeks before participating in the telehealth exercise program as described in Arm I.
Arm B (delayed exercise intervention)Quality-of-Life AssessmentPatients maintain their normal activities of daily living for 8 weeks before participating in the telehealth exercise program as described in Arm I.
Arm B (delayed exercise intervention)Questionnaire AdministrationPatients maintain their normal activities of daily living for 8 weeks before participating in the telehealth exercise program as described in Arm I.
Primary Outcome Measures
NameTimeMethod
Intervention completion rateWeek 9

Will be considered feasible if \>= 75% of enrolled participants successfully complete all study measurements (remote physical function) and \> 50% of patients randomized to the intervention arm are able to complete \> 70% of total exercise sessions (17/24 sessions).

Minimal descriptive statistical analyses will be performed for all participant baseline characteristics and compared across groups to test for balance across the groups, using t-tests (or non-parametric Wilcoxon rank sum) for continuous variables and chi square tests for categorical variables.

Participation rateWeek 9

Rate of participation is defined as number of hematopoietic cell transplantation (HCT) survivors who were approached and participated divided by the total number of eligible HCT survivors who were approached for the study and then multiplied by 100%.

Will be considered feasible if \>= 50% of eligible patients that are approached for participation enroll onto the study.

Minimal descriptive statistical analyses will be performed for all participant baseline characteristics and compared across groups to test for balance across the groups, using t-tests (or non-parametric Wilcoxon rank sum) for continuous variables and chi-square tests for categorical variables.

Secondary Outcome Measures
NameTimeMethod
Changes in the efficacy of the telehealth exercise program on physical functioning - Chair standFrom baseline to week 9

Physical functioning (Chair stand ) will be measured in the unit of time as seconds.

Changes in the efficacy of the telehealth exercise program on physical functioning - Gait speedFrom baseline to week 9

Physical functioning (Gait speed ) will be measured in the unit of time as seconds.

Changes in the efficacy of the telehealth exercise program on physical functioning - Timed balanceFrom baseline to week 9

Physical functioning (Timed balance) will be measured in the unit of time as seconds.

Trial Locations

Locations (1)

City of Hope Medical Center

🇺🇸

Duarte, California, United States

© Copyright 2025. All Rights Reserved by MedPath